Printer Friendly

Volunteers Needed for Stanford Study of Potential Alternative to Ambien.

STANFORD, Calif. -- Could a drug that treats narcolepsy help people with insomnia? Researchers at the Stanford School of Medicine's Sleep Disorders Center will study that question.

The drug, sodium oxybate, is used to treat some symptoms of narcolepsy, a neurological disorder marked by a sudden, uncontrollable urge to sleep. "When we give this agent in narcolepsy, we have an impact on sleep. But also, daytime function is significantly improved and the capacity to remain alert is improved," said Jed Black, MD, assistant professor of psychiatry and behavioral sciences. Because of those effects, he explained, it may also help people who have trouble sleeping.

Black is the lead investigator of an 18-month pilot study to determine whether sodium oxybate can help patients who have trouble sleeping. The study will compare the sleeping pill zoldipem tartrate, marketed as Ambien, with the narcolepsy drug sodium oxybate, marketed as Xyrem.

The study is funded by the Palo Alto-based manufacturer of sodium oxybate, Jazz Pharmaceuticals. Black, the study leader, has done other Jazz-funded studies.

Black and his colleagues are interested in sodium oxybate because it works differently than zoldipem tartrate and other popular prescription sleep medications. Both drugs affect a brain chemical important to sleep called GABA, but they act on GABA in different ways.

Sodium oxybate, also known as gamma hydroxybutyrate or GHB, received approval from the U.S. Food and Drug Administration in 2002 to treat a small population of patients with narcolepsy who experience episodes of cataplexy, a condition characterized by weak or paralyzed muscles.

Patients enrolled in the new study will be randomly assigned to take zoldipem tartrate, sodium oxybate or a placebo for 13 weeks. During this time, researchers at the sleep center will track progress through patient sleep logs, overnight observation at the sleep center and daytime testing.

Overnight visits will "tell us when a person is asleep and what stage of sleep they're in," said Black.

Daytime tests of memory, problem solving and reaction time will help the researchers to determine whether the drugs are helping patients during the day.

Volunteers between the ages of 18 and 75 who regularly have trouble sleeping are needed for the study; researchers aim to enroll 60 people over the next year.

Participants will receive $100 for each of four overnight visits and an additional $150 for completing the study. Prospective volunteers can get more information from clinical coordinator, Paul Stowers, at (650) 725-8910 or

Stanford University Medical Center integrates research, medical education and patient care at its three institutions Co Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children's Hospital at Stanford. For more information, please visit the Web site of the medical center's Office of Communication & Public Affairs at
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Oct 17, 2006
Previous Article:DataDirect Technologies' Shadow z/Services WsC Web Services Consumption Tool Transforms The Mainframe Into Industry Standard Server Providing Direct...
Next Article:Old Point Financial Corporation Announces Third Quarter 2006 Earnings.

Related Articles
All cried out: major depression puts lid on tears. (This week).
Cluster bombs: metabolic syndrome tied to heart disease deaths.
To err is human: influential research on our social shortcomings attracts a scathing critique.
Parental involvement in the classroom.
Senior volunteers live longer.
Staring into the dark: research investigates insomnia drugs.
Ambien users sound alarm over sleepwalking risks.
Pharmacologic management of chronic insomnia.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters